|
1
|
Adès L, Itzykson R and Fenaux P:
Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garcia-Manero G: Myelodysplastic
syndromes: 2014 update on diagnosis, risk-stratification, and
management. Am J Hematol. 89:97–108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Greenberg P, Cox C, LeBeau MM, Fenaux P,
Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al:
International scoring system for evaluating prognosis in
myelodysplastic syndromes. Blood. 89:2079–2088. 1997.PubMed/NCBI
|
|
4
|
Bejar R, Levine R and Ebert BL: Unraveling
the molecular pathophysiology of myelodysplastic syndromes. J Clin
Oncol. 29:504–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alemdehy MF and Erkeland SJ: MicroRNAs:
Key players of normal and malignant myelopoiesis. Curr Opin
Hematol. 19:261–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Navarro A, Gaya A, Martinez A,
Urbano-Ispizua A, Pons A, Balagué O, Gel B, Abrisqueta P,
Lopez-Guillermo A, Artells R, et al: MicroRNA expression profiling
in classic Hodgkin lymphoma. Blood. 111:2825–2832. 2008. View Article : Google Scholar
|
|
9
|
Rokah OH, Granot G, Ovcharenko A, Modai S,
Pasmanik-Chor M, Toren A, Shomron N and Shpilberg O: Downregulation
of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells.
PLoS One. 7:e355012012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang J, Xiang G, Zhang K and Zhou Y:
Expression signatures of intragenic miRNAs and their corresponding
host genes in myeloid leukemia cells. Biotechnol Lett.
34:2007–2015. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Votavova H, Grmanova M, Dostalova
Merkerova M, Belickova M, Vasikova A, Neuwirtova R and Cermak J:
Differential expression of microRNAs in CD34+ cells of
5q- syndrome. J Hematol Oncol. 4:12011. View Article : Google Scholar
|
|
12
|
Lee DW, Futami M, Carroll M, Feng Y, Wang
Z, Fernandez M, Whichard Z, Chen Y, Kornblau S, Shpall EJ, et al:
Loss of SHIP-1 protein expression in high-risk myelodysplastic
syndromes is associated with miR-210 and miR-155. Oncogene.
31:4085–4094. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhagat TD, Zhou L, Sokol L, Kessel R,
Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski
T, et al: miR-21 mediates hematopoietic suppression in MDS by
activating TGF-β signaling. Blood. 121:2875–2881. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song SJ, Ito K, Ala U, Kats L, Webster K,
Sun SM, Jongen-Lavrencic M, Manova-Todorova K, Teruya-Feldstein J,
Avigan DE, et al: The oncogenic microRNA miR-22 targets the TET2
tumor suppressor to promote hematopoietic stem cell self-renewal
and transformation. Cell Stem Cell. 13:87–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Starczynowski DT, Kuchenbauer F,
Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra
M, Wells RA, et al: Identification of miR-145 and miR-146a as
mediators of the 5q- syndrome phenotype. Nat Med. 16:49–58. 2010.
View Article : Google Scholar
|
|
16
|
Deng H, Guo Y, Song H, Xiao B, Sun W, Liu
Z, Yu X, Xia T, Cui L and Guo J: MicroRNA-195 and microRNA-378
mediate tumor growth suppression by epigenetical regulation in
gastric cancer. Gene. 518:351–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang GJ, Zhou H, Xiao HX, Li Y and Zhou
T: MiR-378 is an independent prognostic factor and inhibits cell
growth and invasion in colorectal cancer. BMC Cancer. 14:1092014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sand M, Skrygan M, Georgas D, Sand D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Microarray analysis of
microRNA expression in cutaneous squamous cell carcinoma. J
Dermatol Sci. 68:119–126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu BL, Peng XH, Zhao FP, Liu X, Lu J, Wang
L, Li G, Chen HH and Li XP: MicroRNA-378 functions as an onco-miR
in nasopharyngeal carcinoma by repressing TOB2 expression. Int J
Oncol. 44:1215–1222. 2014.PubMed/NCBI
|
|
20
|
Yin JY, Deng ZQ, Liu FQ, Qian J, Lin J,
Tang Q, Wen XM, Zhou JD, Zhang YY and Zhu XW: Association between
mir-24 and mir-378 in formalin-fixed paraffin-embedded tissues of
breast cancer. Int J Clin Exp Pathol. 7:4261–4267. 2014.PubMed/NCBI
|
|
21
|
Chan JK, Kiet TK, Blansit K, Ramasubbaiah
R, Hilton JF, Kapp DS and Matei D: MiR-378 as a biomarker for
response to anti-angiogenic treatment in ovarian cancer. Gynecol
Oncol. 133:568–574. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee DY, Deng Z, Wang CH and Yang BB:
MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis
by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA.
104:20350–20355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pizzimenti S, Ferracin M, Sabbioni S,
Toaldo C, Pettazzoni P, Dianzani MU, Negrini M and Barrera G:
MicroRNA expression changes during human leukemic HL-60 cell
differentiation induced by 4-hydroxynonenal, a product of lipid
peroxidation. Free Radic Biol Med. 46:282–288. 2009. View Article : Google Scholar
|
|
24
|
Qian J, Lin J, Qian W, Ma JC, Qian SX, Li
Y, Yang J, Li JY, Wang CZ, Chai HY, et al: Overexpression of
miR-378 is frequent and may affect treatment outcomes in patients
with acute myeloid leukemia. Leuk Res. 37:765–768. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Erdogan B, Facey C, Qualtieri J, Tedesco
J, Rinker E, Isett RB, Tobias J, Baldwin DA, Thompson JE, Carroll
M, et al: Diagnostic microRNAs in myelodysplastic syndrome.
Experimental hematology. 39:915–926 e912. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakagawa T, Matozaki S, Murayama T,
Nishimura R, Tsutsumi M, Kawaguchi R, Yokoyama Y, Hikiji K, Isobe T
and Chihara K: Establishment of a leukaemic cell line from a
patient with acquisition of chromosomal abnormalities during
disease progression in myelodysplastic syndrome. Br J Haematol.
85:469–476. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tiscornia G, Singer O and Verma IM:
Production and purification of lentiviral vectors. Nat Protoc.
1:241–245. 2006. View Article : Google Scholar
|
|
28
|
Yang B, Wang L, Luo X, Chen L, Yang Z and
Liu L: SPAG6 silencing inhibits the growth of the malignant myeloid
cell lines SKM-1 and K562 via activating p53 and caspase
activation-dependent apoptosis. Int J Oncol. 46:649–656. 2015.
|
|
29
|
Wang KY, Ma J, Zhang FX, Yu MJ, Xue JS and
Zhao JS: MicroRNA-378 inhibits cell growth and enhances
L-OHP-induced apoptosis in human colorectal cancer. IUBMB Life.
66:645–654. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen LT, Xu SD, Xu H, Zhang JF, Ning JF
and Wang SF: MicroRNA-378 is associated with non-small cell lung
cancer brain metastasis by promoting cell migration, invasion and
tumor angiogenesis. Med Oncol. 29:1673–1680. 2012. View Article : Google Scholar
|
|
31
|
Drexler HG, Dirks WG and Macleod RA: Many
are called MDS cell lines: One is chosen. Leuk Res. 33:1011–1016.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kaplan Y and Kupiec M: A role for the
yeast cell cycle/splicing factor Cdc40 in the G1/S transition. Curr
Genet. 51:123–140. 2007. View Article : Google Scholar
|
|
33
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Imada K: Immunodeficient mouse models of
lymphoid tumors. Int J Hematol. 77:336–341. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Flavell DJ: Modelling human leukemia and
lymphoma in severe combined immunodeficient (SCID) mice: Practical
applications. Hematol Oncol. 14:67–82. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shultz LD, Schweitzer PA, Christianson SW,
Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV,
Greiner DL, et al: Multiple defects in innate and adaptive
immunologic function in NOD/LtSz-scid mice. J Immunol. 154:180–191.
1995.PubMed/NCBI
|
|
37
|
Gibson L, Holmgreen SP, Huang DC, Bernard
O, Copeland NG, Jenkins NA, Sutherland GR, Baker E, Adams JM and
Cory S: bcl-w, a novel member of the bcl-2 family, promotes cell
survival. Oncogene. 13:665–675. 1996.PubMed/NCBI
|
|
38
|
Yan W, Samson M, Jégou B and Toppari J:
Bcl-w forms complexes with Bax and Bak, and elevated ratios of
Bax/Bcl-w and Bak/Bcl-w correspond to spermatogonial and
spermatocyte apoptosis in the testis. Mol Endocrinol. 14:682–699.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rodust PM, Fecker LF, Stockfleth E and
Eberle J: Activation of mitochondrial apoptosis pathways in
cutaneous squamous cell carcinoma cells by diclofenac/hyaluronic
acid is related to upregulation of Bad as well as downregulation of
Mcl-1 and Bcl-w. Exp Dermatol. 21:520–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee HW, Lee SS, Lee SJ and Um HD: Bcl-w is
expressed in a majority of infiltrative gastric adenocarcinomas and
suppresses the cancer cell death by blocking stress-activated
protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res.
63:1093–1100. 2003.PubMed/NCBI
|
|
42
|
Wilson JW, Nostro MC, Balzi M, Faraoni P,
Cianchi F, Becciolini A and Potten CS: Bcl-w expression in
colorectal adenocarcinoma. Br J Cancer. 82:178–185. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sanjmyatav J, Steiner T, Wunderlich H,
Diegmann J, Gajda M and Junker K: A specific gene expression
signature characterizes metastatic potential in clear cell renal
cell carcinoma. J Urol. 186:289–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS,
Choi KM and Um HD: Bcl-w promotes gastric cancer cell invasion by
inducing matrix metalloproteinase-2 expression via phosphoinositide
3-kinase, Akt, and Sp1. Cancer Res. 66:4991–4995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang F, Liu M, Li X and Tang H: MiR-214
reduces cell survival and enhances cisplatin-induced cytotoxicity
via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett.
587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wallach D, Varfolomeev EE, Malinin NL,
Goltsev YV, Kovalenko AV and Boldin MP: Tumor necrosis factor
receptor and Fas signaling mechanisms. Annu Rev Immunol.
17:331–367. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li P, Nijhawan D, Budihardjo I,
Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and
dATP-dependent formation of Apaf-1/caspase-9 complex initiates an
apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Goldar S, Khaniani MS, Derakhshan SM and
Baradaran B: Molecular mechanisms of apoptosis and roles in cancer
development and treatment. Asian Pac J Cancer Prev. 16:2129–2144.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Boudard D, Vasselon C, Berthéas MF,
Jaubert J, Mounier C, Reynaud J, Viallet A, Chautard S, Guyotat D
and Campos L: Expression and prognostic significance of Bcl-2
family proteins in myelodysplastic syndromes. Am J Hematol.
70:115–125. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Parker JE, Fishlock KL, Mijovic A,
Czepulkowski B, Pagliuca A and Mufti GJ: ‘Low-risk’ myelodysplastic
syndrome is associated with excessive apoptosis and an increased
ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J
Haematol. 103:1075–1082. 1998. View Article : Google Scholar
|
|
52
|
Parker JE, Mufti GJ, Rasool F, Mijovic A,
Devereux S and Pagliuca A: The role of apoptosis, proliferation,
and the Bcl-2-related proteins in the myelodysplastic syndromes and
acute myeloid leukemia secondary to MDS. Blood. 96:3932–3938.
2000.PubMed/NCBI
|
